Manila Times Business
Memo Therapeutics AG Presents Further Analyses of the Phase II Trial Results of Potravitug for the Treatment of BKPyV Infection in Kidney Transplant Recipients in an Oral Presentation at the 63rd European Renal Association Congress
PRESS RELEASE First-in-class therapeutic antibody, potravitug, for BK polyomavirus infection showed consistent reduction in viral load and biopsy-proven BKPyVAN in a Phase II study in kidney transplant recipients Propensity Score Matching against large real‑world cohort shows statistically significant viral clearanceSchlieren / Zurich, Switzerland, 5 June, 2026 - Memo Therapeutics AG ("MTx”), a late-stage biotech company translating unique immune responses into superior medicines to treat viral
This is an excerpt. Read the full article at the original source:
Source: manilatimes.net
Read Full Article on manilatimes.net →More from Manila Times Business
Granite Credit Union Invites Community to Celebrate Eagle Mountain Grand Opening
Just now
Rivus Pharmaceuticals Announces Preclinical Data for RV-8451, a Muscle-Preserving, Oral GLP-1, at ADA 2026 Scientific Sessions
Just now
E.F. Hutton & Co. Will Serve as Platinum Sponsor at The SPAC Conference 2026
Just now
Family questions rescue efforts for Sherpa guide found alive on Everest
Just now